Inside the procedure at the heart of a multibillion-dollar race to a safer AFib treatment
Medtech executives expect the technology to help fuel their companies’ future growth. Boston Scientific CEO Mike Mahoney has ...
MassDevice19d
FDA grants breakthrough nod to pulsed field ablation tech from Farapulse founder’s Field Medical
Field Medical announced today that it received FDA breakthrough device designation for its FieldForce pulsed field ablation ...
medtechdive8d
PFA to surpass radiofrequency ablation in 2025: Citi survey
Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...
ECU Health performs first procedure using FARAPULSE
GREENVILLE, N.C. (WITN) - An Eastern Carolina hospital recently performed its first procedure with a new and innovative ...
Boston Scientific price target raised to $107 from $98 at Citi
Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...
Boston Scientific’s Promising Clinical Trials and Innovative Approaches Justify Buy Rating
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...
Yahoo Finance1mon
Medtronic’s ablation sales slowed by PFA supply issues
The supply disruption came in the same quarter that Boston Scientific saw strong demand for its rival PFA device, Farapulse. Boston Scientific said in October that Farapulse drove a 177% sales ...
Yahoo Finance8d
PFA to surpass radiofrequency ablation in 2025: Citi survey
Four PFA systems have launched in the U.S. in the past year: Medtronic’s PulseSelect and Affera Sphere-9, Boston Scientific’s Farapulse and J&J's Varipulse. The Citi survey polled 36 ...